Aldospray (Aerosol) Instructions for Use
Marketing Authorization Holder
Aldo-Union, S.A. (Spain)
ATC Code
M02AA (Topical non-steroidal anti-inflammatory drugs)
Active Substance
Mabuprofen (Rec.INN registered by WHO)
Dosage Form
| Aldospray | Aerosol for external use 10%: canister 90 g |
Dosage Form, Packaging, and Composition
Aerosol for external use 10% in the form of a homogeneous foamy mass of white color.
| 1 g | |
| Mabuprofen | 100 mg |
Excipients: dimethyl sulfoxide, cetyl alcohol, Siegert L-2-SM esterin, polyethylene 23 lauryl ether, sorbitan monostearate, sorbitan monooleate, triethanolamine, propylene glycol, povidone, benzyl alcohol, 1,1,1,2-tetrafluoroethane (propellant 134a), purified water.
90 g – aluminum canisters (1) with a polypropylene sprayer and a cap – cardboard packs.
Clinical-Pharmacological Group
NSAIDs for external use
Pharmacotherapeutic Group
NSAID
Pharmacological Action
NSAID for external use, an ibuprofen derivative. It has a pronounced anti-inflammatory and analgesic effect. The mechanism of action is associated with inhibition of prostaglandin synthesis due to non-selective blockade of COX1 and COX2.
Pharmacokinetics
When applied externally, Mabuprofen is absorbed and undergoes hydrolysis, resulting in the release of ibuprofen. Systemic bioavailability is up to 18%.
The binding of ibuprofen to plasma proteins is 90%. During biotransformation, 4 metabolites are formed: 2-p-(2-hydroxy-2-methylpropyl) phenylpropionic acid, 2-p-(carboxypropyl) phenylpropionic acid), 2-4-(2-hydroxymethylpropyl) phenylpropionic acid, 2-4-(1-hydroxy-2-methylpropyl) phenylpropionic acid.
Up to 60% is excreted by the kidneys: about 9% as oxidized metabolites, up to 17% as conjugated oxidized metabolites, 16% as carboxylated metabolites, 19% as conjugated carboxylated metabolites.
Indications
Inflammatory and degenerative diseases of the musculoskeletal system (including rheumatoid arthritis in remission stage, arthralgia in rheumatism, gout /as part of complex therapy/, psoriatic arthritis, shoulder periarthritis, ankylosing spondylitis, deforming osteoarthritis, osteochondrosis with radicular syndrome, radiculitis, sciatic nerve neuritis, tendonitis, tenosynovitis, bursitis, low back pain).
Injuries (including sports, occupational, domestic) without violation of the integrity of soft tissues (including dislocations, sprains or ruptures of muscles and ligaments, contusions, post-traumatic soft tissue edema).
Pain syndrome of various origins (postoperative pain, neuralgia, tendonitis, bursitis, radiculitis, traumatic inflammation of soft tissues and the musculoskeletal system).
Myalgia of various origins.
Superficial phlebitis, periphlebitis (as part of combination therapy).
ICD codes
| ICD-10 code | Indication |
| I80 | Phlebitis and thrombophlebitis |
| M05 | Seropositive rheumatoid arthritis |
| M07 | Psoriatic and enteropathic arthropathies |
| M10 | Gout |
| M13.9 | Arthritis, unspecified |
| M15 | Polyosteoarthritis |
| M19.9 | Unspecified arthrosis |
| M25.5 | Pain in joint |
| M42 | Spinal osteochondrosis |
| M45 | Ankylosing spondylitis |
| M47 | Spondylosis |
| M54.1 | Radiculopathy |
| M54.3 | Sciatica |
| M54.4 | Lumbago with sciatica |
| M65 | Synovitis and tenosynovitis |
| M70 | Soft tissue disorders related to use, overuse, and pressure |
| M71 | Other bursopathies |
| M75.0 | Adhesive capsulitis of shoulder |
| M79.1 | Myalgia |
| M79.2 | Neuralgia and neuritis, unspecified |
| R52.0 | Acute pain |
| R52.2 | Other chronic pain |
| T14.0 | Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect) |
| T14.3 | Dislocation, sprain and strain of joint and ligament of unspecified body region |
| ICD-11 code | Indication |
| 8B93.Z | Radiculopathy, unspecified |
| 8E4A.1 | Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system |
| BD70.0 | Superficial thrombophlebitis of lower extremities |
| BD70.Z | Superficial thrombophlebitis, unspecified |
| BD71.4 | Deep vein thrombosis of lower extremity |
| BD7Z | Diseases of veins, unspecified |
| EH92 | Dermatoses provoked by friction or mechanical impact |
| EH92.1 | Blister due to friction |
| FA05 | Polyosteoarthritis |
| FA0Z | Osteoarthritis, unspecified |
| FA20.0 | Seropositive rheumatoid arthritis |
| FA21.Z | Psoriatic arthritis, unspecified |
| FA25 | Gout |
| FA2Z | Inflammatory arthropathies, unspecified |
| FA85.Z | Defects of vertebral end-plates, unspecified |
| FA8Z | Degenerative disease of spine, unspecified |
| FA92.0Z | Ankylosing spondylitis, unspecified |
| FB40.Z | Tenosynovitis, unspecified |
| FB50.1 | Bursitis associated with use, overuse or pressure |
| FB50.Z | Bursitis, unspecified |
| FB53.0 | Adhesive capsulitis of shoulder |
| FB56 | Specified soft tissue diseases, not elsewhere classified |
| FB56.2 | Myalgia |
| ME82 | Pain in joint |
| ME84.20 | Lumbago with sciatica |
| ME84.3 | Sciatica |
| MG30.Z | Chronic pain syndrome, unspecified |
| MG31.Z | Acute pain, unspecified |
| ND56.0 | Superficial injury of unspecified body region |
| ND56.3 | Dislocation, sprain or strain of unspecified body region |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For external use only. Apply the aerosol to intact skin over the painful area.
Shake the canister vigorously immediately before each use.
Hold the canister upright and spray from a distance of approximately 10-15 cm (4-6 inches).
Apply a sufficient amount to cover the entire affected area with a thin, uniform layer.
Administer the spray two to three times daily. The interval between applications should be at least four hours.
Gently massage the foam into the skin until fully absorbed.
Wash hands thoroughly with soap and water after application, unless the hands are the treated area.
The duration of continuous use should not exceed ten days for analgesia or fourteen days for anti-inflammatory effect without medical consultation.
Discontinue use and consult a physician if symptoms persist or worsen.
Avoid covering the treated area with occlusive dressings or tight bandages unless directed by a physician.
Adverse Reactions
Rarely erythema, burning sensation at the application site.
Contraindications
Hypersensitivity to mabuprofen.
Special Precautions
During application, avoid contact of the active substance with open wound surfaces and mucous membranes.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Mildronate capsules 500mg, 90pcs
Belosalic, ointment, 30g
No-spa pills 40mg, 64pcs
Actovegin pills 200mg, 50pcs
Cortexin, 10mg, 5ml, 10pcs
Belosalic, lotion solution for external use spray 100ml
Daivobet, ointment, 30g
Kagocel pills 12mg, 30pcs
Picamilon pills 50mg, 60pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs 